Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety-Reference-Cited by-同舟云学术

Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

Published:2017 Issue:26 Volume:23 Page:4759
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Latt Nyan L,Yanny Beshoy T,Gharibian Derenik,Gevorkyan Rita,Sahota Amandeep K

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference14 articles.

1. Chronic Hepatitis C Infection

2. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

3. Toward a more accurate estimate of the prevalence of hepatitis C in the United States

4. Prevalence and Challenges of Liver Diseases in Patients With Chronic Hepatitis C Virus Infection

5. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study;The Korean Journal of Internal Medicine;2022-11-01

2. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

3. Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial;Viruses;2022-03-16

4. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis;Frontiers in Medicine;2021-06-08

5. Synthesis and Anti-HCV Activity of Sugar-Modified Guanosine Analogues: Discovery of AL-611 as an HCV NS5B Polymerase Inhibitor for the Treatment of Chronic Hepatitis C;Journal of Medicinal Chemistry;2020-08-20